ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
The National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Annual Meeting took place on October 17-18. Here are some highlights on a selection of many of the topics and interactions over that meeting.
“When are we going to cure cancer?” If I had a dime for every time I’ve been asked that...The trite answer is that we already cure many cancers, just not enough of them! But the real question should be, “Why don’t we cure all cancers?”
Inequalities, especially in health care, breed discontent. We need better ways to continue incentivizing the development of new drugs while optimizing access. Biosimilars help, but they won't solve the whole problem.
Many of the successful, FDA-approved drugs commonly used in cancer care were developed at small biotech or pharma companies—so what role do the "big fish" play?
Support for federal research funding for cancer is not about politics. It's about people. There is no one in our society—liberal, conservative, libertarian, or just don’t care—who isn’t touched in some way by cancer.
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.
The ASCO Research Community Forum Annual Meeting is in September. As Chair of the Research Community Forum Council, I’m very excited about what’s in store for this year’s meeting and would like to encourage all researchers and research staff to join us for this enriching event.
Drug companies play a key role in improving cancer care, but financial toxicity for patients continues to worsen. Eternal vigilance is the price of liberty from excessive drug costs, and we have an ethical obligation to hold pharmaceutical companies accountable.
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
How we report clinical trials makes interpreting their results harder. Why shouldn’t we all have more information to make better decisions for our patients?
Deciding whether RNI works depends upon not only accurate risk assessment but also a better understanding of the disease. Here are some key elements of breast cancer and treatment that aren’t adequately decided just by looking at pathologic stage, grade, and surgery type.
To determine when radiation helps treat lymph nodes, we need to carefully interpret surgical findings and accurately stage breast cancer to best understand the risk of lymph node involvement.
Two recently published large clinical trials, NCIC MA.20 and EORTC 22922, raised a lot of interest in and a lot of questions about when radiation helps for treating lymph nodes in breast cancer. The data are more complicated than often presented.
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.
ASCO CEO Dr. Allen S. Lichter reflects on an optimistic approach to the challenges of providing high-quality cancer care around the globe on World Cancer Day.
Prevention is better than cure—an age-old saying, but one that is highly relevant in these times of increasing incidence of diseases and skyrocketing health care costs, notes Dr. Monica Malik.
Blogs
ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
No Results.
Pages
Advertisement